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Two developments, which simultaneously and independently occurred 
in the 1980s, have substantially impacted the way drugs are currently 
being discovered and developed. First, there was a significant change in 
the technology employed for drug discovery. Traditionally, drugs were 
discovered using organs, tissues, cells or extracts thereof in screens to 
identify active pharmaceuticals. These traditional methodologies have 
been replaced by the use of technology involving specific molecular 
targets. These biotechnological targets may be receptors responsible for 
unique cell interactions associated with a disease or an enzyme that can 
catalyze a distinct biochemical reaction associated with a disease. The 
ability to identify and produce these unique proteins by recombinant 
techniques has resulted, in turn, in a wide range of mechanism-based 
screens. Of the 40 top selling drugs (worldwide sales 1993), 25 were 
identified by a specific mechanism of action: 13 were receptor agonists/ 
antagonists; eight were enzymes/protease inhibitors; and four were 
channel blockers.
Second, the unencumbered availability of the materials and processes 
used in drug discovery has been noticeably decreasing. Prior to the rapid 
development of biotechnology, most pharmaceutical or chemical patents 
claimed active therapeutic agents, intermediates leading to active agents, 
processes of making active agents and intermediates, and methods of 
using active agents. The basic methodologies for chemical research were 
not generally patented. In 1980, Congress passed both the Stevenson-
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Wydler Technology Innovation Act1 and the Bayh-Dole Act2 . Together, 
these Acts allowed government contractors, small businesses and nonprofit 
organizations to retain certain patent rights in government sponsored 
research and permitted the funded entity to transfer the technology to third 
parties. The original legislation was expanded in 1983 by Presidential Order3 
to include all government contractors. The 1980 legislation and subsequent 
amendments4 (collectively termed Bayh-Dole) permit the contractor to grant 
exclusive licenses to government-funded contractor inventions. With the 
passage of the Federal Technology Transfer Act of 19865, Congress 
authorized federal laboratories to enter into cooperative research and 
development agreements (CRADAs) with private companies. The Act also 
required federal laboratories to agree in advance to assign or license to 
the collaborating party patents on inventions made by federal employees 
in the course of the collaborative research.
The stated intent of Bayh-Dole was to ensure that the patented results 
of federally funded research would be broadly and rapidly available for all 
scientific investigation, irrespective of the objectives of the research and 
the terms under which licenses are granted for the sale of products under 
the patents. Bayh-Dole effectively shifted federal policy from a position of 
putting the results of government-sponsored research directly into the public 
domain for use by all, to a pro-patent position that stressed the need for 
exclusive rights as an incentive for industry to undertake the costly invest-
ment necessary to bring new products to market. As a result, many of the 
basic materials and laboratory procedures that are universal to biotechnology 
and modern drug discovery have been the subject of patents and patent 
applications. As a result, accessibility is restricted.
The biotechnology materials and procedures that enhance drug discovery 
have been termed Research Tools. Research Tools are defined herein as 
biological or biochemical materials or processes that are useful for drug 
discovery and exclude materials or processes when used commercially. 
Examples of Research Tools include cDNA clones, receptors, monoclonal 
antibodies, transgenic animals and other inventions that can be used for 
drug discovery.
'Pub. L. No. 96-480, 94 Stat. 2311 (1980) (codified as amended at 15 U.S.C. §§ 3701-3714).
2Pub. L. No. 96-517, § 6(a), 94 Stat. 3015, 3019-27 (1980) (codified as amended at 35 U.S.C. §§ 201- 
211) .
'Presidential Memorandum to the Heads of Executive Departments and Agencies, Subject: govern-
ment Patent Policy, 1983 Pub. Papers 248.
4Pub. L. No. 98-620, 98 Stat. 3335 [Trademark Clarification Act of 1984).
3Pub. L. No. 99-502, 100 Stat. 1785 (amending the Stevenson-Wydler Technology Innovation Act
of 1980).
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It is well recognized that one purpose of Bayh-Dole is to permit government 
funded patentees to grant exclusive licenses for the commercialization of 
products. This purpose can be accomplished while the broader intent of the 
Acts — that inventions be utilized as broadly as possible, is met. Accordingly, 
we believe that a federally funded patentee should grant non-exclusive licenses 
for Research Tools independent of licenses for products for sale. Further, we 
believe that the non-exclusive licenses should be available for reasonable fees. 
This broad access to Research Tools discovered under federally funded research 
programs by a non-exclusive license acts to foster competition among com-
mercial laboratories to discover and ultimately develop novel human health 
products, thereby meeting the Congressional intent of Bayh-Dole. Because 
Merck supports a policy of licensing of patented inventions for research use 
separately from licensing for commercial development of products for sale, 
Merck Research Tool inventions are accessible for research purposes.
The current avalanche of genetic information from the Human Genome 
Project and other sequencing sources promises even greater advances for 
molecular medicine from Research Tools identified by these programs. With 
a complete, high resolution map of the human genome and an understanding 
of the genetic basis for disease, scientists should be able to create mechanism- 
based drugs that will result in improved therapies for known diseases and 
new therapies for diseases as yet unconquered. For this to happen in a timely 
manner, the basic Research Tools required for drug discovery must be readily 
available to the academic, governmental and industrial biomedical research 
community. Thus, availability will likely depend on ownership of genes and 
gene products and the methods of using those gene products.
Ownership of human genes first became a national and international issue 
when in 1992, the National Institutes of Health (NIH) filed patent applications 
claiming thousands of partial cDNA sequences which Craig Venter had termed 
expressed sequence tags (EST) (Adams et al. 1991). The NIH claimed the EST 
patent applications were filed to preserve a proprietary position for presumed 
valuable inventions (McGregor 1992). The NIH assumed that patent claims 
would issue with sufficient breadth to attract licensees that would develop 
products related to the partial genes. The NIH applications, however, created 
a worldwide controversy. American scientists associated with the human 
genome project strongly opposed the filing of EST patent applications because 
they believed the patents would have a negative impact on genome research 
(Roberts 1991). The science ministries of numerous European countries were 
very outspoken about how the patenting of genetic information would likely 
slow down the human genome project and change the economics of biomedical 
research. Due to the outcry from the worldwide scientific community and the 
inability to overcome the U.S. Patent and Trademark Office’s (USPTO) rejection 
of the applications claims, the NIH simply did not respond to actions from the 
USPTO and the applications went abandoned.
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The NIH applications raised questions about the patentability of human gene 
segments. The USPTO has issued patents claiming isolated and purified DNA 
(cDNA or genomic DNA) which encode a functional protein of known activity. 
Indeed, patents have been issued on short DNA fragments that are useful as 
diagnostics. The issuance of DNA patents requires that a compound (a gene, 
genomic sequence or cDNA sequence) must have been removed from its 
natural setting, be new, useful, unobvious and be enabled by the patent 
application.6 An invention is considered novel if it has not been placed in the 
public domain, i.e., is not described in a publication or placed in commerce.
The utility requirement can generally be met by demonstrating a particular 
use, such as a DNA sequence for gene therapy or as an intermediate for the 
manufacture of the encoded protein with an established function. A nonobvious 
invention is one that could not have been made with a reasonable expectation 
of success by a hypothetical person of “ordinary skill” in the relevant scientific 
field from publicly available information. Enablement requires that a patent 
application teach one skilled in the scientific area how to make and use the 
invention. In the case of the NIH partial sequences (EST) as discussed above, 
the USPTO maintained that the ESTs did not meet the utility requirement nor 
did the applications enable the inventions.
The Court of Appeals for the Federal Circuit (CAFC) has affirmed the 
validity of claims to full length cDNA or genomic DNA molecules, e.g., human 
erythropoietin and insulin like growth factor.7 Indeed, obtaining a patent on 
a specific DNA molecule is quite beneficial in developing a patent portfolio 
around a specific protein therapeutic. In some instances, the protein may be 
known and not patentable and the only patent protection available will be for 
the isolated and purified DNA that can be used to make the protein therapeutic. 
This is important because large proteins may not be economically made by 
nonbiotechnological means. Product exclusivity through patent protection is 
required to offset the high research and development costs and the extended 
time to bring a product to market. The current estimate for this high risk 
enterprise is an average of 12 years from discovery to market and an investment 
of over $350 million.
With the lapse of the NIH EST patent applications the subject matter 
entered the public domain and was available to all researchers. The scientific 
community hoped that all genomic Research Tools would be readily available 
for biomedical research. Unfortunately, the privatization of EST research has 
thwarted this goal.
635 U.S.C. §§ 100-103 and 35 U.S.C. § 112.
7Amgen Inc. v. Chugai Pharmaceutical Co., 927 E 2d 1200,18 USPQ2d 1016 (Fed. Cir.), cert, denied, 
502 U.S. 856 (1991) and In re Bell, 991E 2nd 781; 26 USPQ2d 1529 (Fed. Cir. 1993)
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Several organizations are attempting to establish proprietary control over 
much of the sequence data on expressed human genes, including ESTs. Com-
panies such as Human Genome Sciences (HGS) and Incyte are generating large 
EST data bases and are licensing access on an exclusive or non-exclusive basis 
to commercial entities (Dickson 1994a; Gen. Tech. News 1994). HGS initially 
maintained control over the utilization of the cDNA resources in their database 
and restricted access to collaborators, such as SmithKline Beecham, who were 
willing to invest significant sums of money for sequence information and rights 
to patented genes. Recently HGS has allowed academics limited access to the 
database but only if the institution agrees to allow HGS to develop any product 
identified by the use of the information gained from the database (Dickson 
1994b). Unfortunately, this type of private ownership may prevent genomic 
scientists from pursuing full-length sequencing, mapping, and gene-based 
discoveries that would realize the goals to the Human Genome Project.
Merck has taken the view that the information represented by ESTs should 
be made broadly available with no commercial obligations. Indeed, access to the 
ESTs plus the corresponding physical cDNA clone will provide the key Research 
Tools that will speed the development of new biomedical knowledge. This 
knowledge should lead to new therapeutics for a wide range of diseases as the 
underlying pathophysiological mechanisms are better understood. The medical 
and commercial results of these efforts will benefit all interested parties, while 
providing opportunities and preserving incentives for investment in gene-based 
product development.
To this end, Merck has organized a collaborative effort termed the Merck 
Gene Index Project. This effort will make cDNA resources rapidly available 
to all scientists, for gene identification and mapping (Williamson and Elliston 
1994). The Merck Gene Index will be a catalog of sequence data and identified 
clones arrayed from numerous cDNA libraries representing various organs 
and tissues and a variety of developmental stages. All scientists, whether 
public or private, will have full access to this standard set representing one 
clone per unique expressed gene. These clones will be characterized by single 
pass DNA sequencing and will be arrayed into microtitre plates and on filters 
as a publicly available resource. In cooperation with the IMAGE consortium 
(Integrated Molecular Analysis of Gene Expression), coordinated by Greg 
Lennon of Lawrence Livermore National Laboratory, a set of appropriate 
clones will be identified for sequencing by Robert Waterston, Richard Wilson, 
and their colleagues at the Genome Sequencing Center of the Washington 
University School of Medicine in St. Louis, Missouri. By identifying the 
repetitive and uniquely expressed genes, the number of clones that must 
be sequenced to capture all unique genes in a given sample should be reduced 
by an order of magnitude.
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Washington University will generate sequence data from both the 5' and 3' 
ends of about 200,000 individual cDNA clones. The 3’ end sequences will help 
facilitate mapping and full-length sequencing of specific cDNAs on human 
chromosomes, and facilitate the identification of a minimal set of unique gene 
cDNAs. The 5' end sequences will assist in identifying human cDNA sequence 
similarity to proteins of known function in existing databases. The new 
sequence data generated by Washington University will be submitted regularly 
via Database EST to Genbank (managed by the National Center for Biotech-
nology Information) where all interested researchers will have immediate and 
unrestricted access to the data, not only in the U.S., but also through Genbank’s 
collaborative arrangements with its international partners, including the 
European Bioinformatics Institute, National Center for Genomic Resources 
and DNA Database of Japan. All users will be asked, though not required, to 
contribute results obtained using the Merck Gene Index data and/or clones to 
appropriate public databases.
The set of roughly 200,000 cDNA clones to be sequenced by Washington 
University will also be available from appropriate commercial and not-for-profit 
organizations, in the form of polymerase chain reaction (PCR) products gridded 
onto nylon membranes, and as individual clones and sets of clones in 384-well 
plates. These resources will then be distributed at reasonable cost via estab-
lished networks to researchers who wish to do sequencing and mapping of 
individual genes or sets of genes, or for any research purpose.
This effort is anticipated to characterize between 50 percent and 85 percent 
of the unique expressed human genes, and to increase dramatically the amount 
and quality of publicly available sequence information on expressed genes. 
Scientists worldwide will have ready access to and be able to exploit particular 
clones as singletons or sets. The associated bioinformatics effort will ensure that 
the data generated are also captured in standardized fashion and made broadly 
available in public databases. These subsequent efforts using the Merck Gene 
Index as a research resource will likely lead to the identification of nearly 100 
percent of expressed human genes.
The continued expansion of biomedical science and the discovery and 
development of unique highly specific therapeutics will depend on the 
availability of Research Tools to the academic, governmental and commercial 
research scientists. This can best be accomplished by having federally funded 
Research Tools available non-exclusively and by encouraging collaborations 
between commercial laboratories and academic and governmental laboratories 
to develop Research Tools, such as the Merck Gene Index. This broad access to 
Research Tools will advance science, accelerate the progress of medicine, and 
foster competition among commercial laboratories to discover and ultimately 
develop new human health products that will benefit all.
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